These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 23434351

  • 1. Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial.
    Gervais R, Robinet G, Clément-Duchêne C, Denis F, El Kouri C, Martin P, Chouaki N, Bourayou N, Morère JF.
    Lung Cancer; 2013 May; 80(2):185-90. PubMed ID: 23434351
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M.
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [Abstract] [Full Text] [Related]

  • 3. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
    Zukin M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, do Nascimento YN, Murad A, Franke FA, Precivale M, Araujo LH, Baldotto CS, Vieira FM, Small IA, Ferreira CG, Lilenbaum RC.
    J Clin Oncol; 2013 Aug 10; 31(23):2849-53. PubMed ID: 23775961
    [Abstract] [Full Text] [Related]

  • 4. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M.
    Clin Lung Cancer; 2013 May 10; 14(3):215-23. PubMed ID: 23332288
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD.
    J Clin Oncol; 2009 Jul 10; 27(20):3284-9. PubMed ID: 19433684
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
    Kim YH, Hirabayashi M, Kosaka S, Nikaidoh J, Yamamoto Y, Shimada M, Toyazaki T, Nagai H, Sakamori Y, Mishima M.
    Cancer Chemother Pharmacol; 2013 Jun 10; 71(6):1445-51. PubMed ID: 23532206
    [Abstract] [Full Text] [Related]

  • 7. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
    Xu Y, Ma S, Ji Y, Sun X, Jiang H, Chen J, Du X, Zheng Y, Qiu G.
    Lung Cancer; 2011 Jun 10; 72(3):327-32. PubMed ID: 21056507
    [Abstract] [Full Text] [Related]

  • 8. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.
    Malhotra B, Evans T, Weiss J, Eaby B, Stonehouse-Lee S, Sherry V, Langer CJ.
    Clin Lung Cancer; 2010 May 10; 11(3):192-7. PubMed ID: 20439196
    [Abstract] [Full Text] [Related]

  • 9. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.
    Lancet Oncol; 2012 Mar 10; 13(3):247-55. PubMed ID: 22341744
    [Abstract] [Full Text] [Related]

  • 10. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ.
    J Clin Oncol; 2009 Apr 20; 27(12):2038-45. PubMed ID: 19307503
    [Abstract] [Full Text] [Related]

  • 11. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE.
    Clin Cancer Res; 2007 Jan 15; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
    Karayama M, Inui N, Kuroishi S, Yokomura K, Toyoshima M, Shirai T, Masuda M, Yamada T, Yasuda K, Suda T, Chida K.
    Cancer Chemother Pharmacol; 2013 Aug 15; 72(2):445-52. PubMed ID: 23807323
    [Abstract] [Full Text] [Related]

  • 14. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
    Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, O'Brien M, Peterson PM, Castellano D, Selvaggi G, Novello S, Blatter J, Kayitalire L, Crino L, Paz-Ares L.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):690-6. PubMed ID: 15701857
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.
    Stevenson JP, Langer CJ, Somer RA, Evans TL, Rajagopalan K, Krieger K, Jacobs-Small M, Dyanick N, Milcarek B, Coakley S, Walker S, Eaby-Sandy B, Hageboutros A.
    Cancer; 2012 Nov 15; 118(22):5580-7. PubMed ID: 22544579
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.